15-keto-13-14-dihydroprostaglandin-f2alpha and formestane

15-keto-13-14-dihydroprostaglandin-f2alpha has been researched along with formestane* in 1 studies

Other Studies

1 other study(ies) available for 15-keto-13-14-dihydroprostaglandin-f2alpha and formestane

ArticleYear
Effects of dibutyryl cAMP, LHRH, and aromatase inhibitor on simultaneous outputs of prostaglandin F2 alpha, and 13,14-dihydro-15-keto-prostaglandin F2 alpha by term placental explants.
    Prostaglandins, 1982, Volume: 23, Issue:1

    Explants from term human placentas were maintained in culture with daily changes of medium. Daily output of PGF2 alpha and PGFM1 decreased during the course of the incubation. Addition of 4 micrograms/ml DHEAS or 67 micrograms/ml LDL cholesterol had no effect on output of PGF2 alpha or PGFM. Addition of 1.6, 3.2, or 6.4 micrograms/ml of LHRH to the culture plates had no effect on output of PGFM or PGF2 alpha, but LHRH increased hCG output. Dibutyryl cAMP (1mM, 2mM, and 4 mM) increased output of PGF2 alpha, PGFM, and hCG. Aromatase inhibitor decreased hCG output, but it was without effect on output of PGF2 alpha, or PGFM, Significant correlations were demonstrated between progesterone, PGFM, PGF2 alpha, and hCG, suggesting that PGF2 alpha originates in the syncytiotrophoblast cell. The ability of LHRH to stimulate output of hCG but not PGF2 alpha while dbcAMP stimulated both suggests that either PGF2 alpha and hCG arise in different cells or that LHRH does not act through cAMP.

    Topics: Androstenedione; Aromatase Inhibitors; Bucladesine; Chorionic Gonadotropin; Culture Techniques; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dinoprost; Female; Gonadotropin-Releasing Hormone; Humans; Kinetics; Lipoproteins, LDL; Placenta; Pregnancy; Prostaglandins F

1982